Regimen Simplification to Atazanavir‐Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48‐Week Clinical and Virologic Outcomes | Zendy

Timothy Wilkin | Zendy; John E. McKin | Zendy; A. Gregory DiRienzo | Zendy; Katie R. Mollan | Zendy; Courtney V. Fletcher | Zendy; David M. Margolis | Zendy; Barbara Bastow | Zendy; Gary Thal | Zendy; William C. Woodward | Zendy; Catherine Godfrey | Zendy; Ann Wiegand | Zendy; Frank Maldarelli | Zendy; Sarah Palmer | Zendy; John M. Coffin | Zendy; John W. Mellors | Zendy; Susan Swindells | Zendy

Open Access

Regimen Simplification to Atazanavir‐Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48‐Week Clinical and Virologic Outcomes

Author(s) -

Timothy Wilkin,

John E. McKin,

A. Gregory DiRienzo,

Katie R. Mollan,

Courtney V. Fletcher,

David M. Margolis,

Barbara Bastow,

Gary Thal,

William C. Woodward,

Catherine Godfrey,

Ann Wiegand,

Frank Maldarelli,

Sarah Palmer,

John M. Coffin,

John W. Mellors,

Susan Swindells

Publication year - 2009

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/597119

Subject(s) - atazanavir , ritonavir , medicine , viral load , viremia , regimen , discontinuation , protease inhibitor (pharmacology) , virology , immunology , antiretroviral therapy , human immunodeficiency virus (hiv)

Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)-sparing benefits, low pill burden, once-daily dosage, and safety.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research